An investigation of the uncomfortable relationship amongst the threeRead more...
And a big congratulations to our People's Choice winner, Privail!
(Image: Jules Walker (KPMG), Bambi Francisco (Vator), Sidd Sinha (Founder & CEO, Luminate Health), Jessica Hsu (Founder & CTO)
The ballots are in! They have all been counted and recounted, and we have a winner for this year's Vator Splash Health is... Luminate Health!
Luminate Health is a patient portal for lab results.
The company gives labs a first-of-its-kind digital platform for their patients to access and understand their lab results. Luminate Health is also helping these labs satisfy a major new federal rule from HHS, which now requires all US labs - commercial, specialty, and hospital labs - to provide patients with direct access to their lab results.
Luminate Health now counts a number of top-150 US labs among its customers and continues to see a very positive response to its product from both patients and physicians.
Privail is a point of care diagnostics for early detection of disease.
The company is developing point-of-care (POC) diagnostics for the early detection of infectious diseases, with an initial focus on HIV. Unlike current POC diagnostic methods, which focus on the detection of antibodies or nucleic acids, Privail's proprietary technology directly detects the virus itself and is available in a simple, low-cost and portable device. By getting tested immediately, patients can receive earlier and more effective treatment, and ultimately reduce the spread of disease.
By providing affordable tests that can be conducted in the privacy of one's home, Privail sets the stage for enhanced health outcomes on a global level. The earlier HIV is detected, the better patients can avoid contracting AIDS and inadvertently spreading the virus. Furthermore, earlier diagnosis allows these patients to receive earlier treatment and increase the length and quality of their lives.
And a big thank you to all of our other finalists who presented today;
Core Mobile, a workflow platform at hospitals, particularly surgery/operations
The company makes healthcare mobile, efficient and coordinated, in order to achieve three objectives: to omprove efficiency to reduce healthcare costs; to omprove healthcare staff satisfaction; and to improve patient outcomes and patient family satisfaction by reducing readmissions and revists leveraging population health.
Core Mobile achieves the 3 objectives by combining mobile technologies, location based technologies and predictive analytics into ONE software solution called Corey, which provides care coordination within hospital and post-acute care settings; workflow optimization in perioperative services, ambulatory services, emergency department, primary care, surgical and post acute care services and home care services; and Medication schedule & discharge instruction compliance for reducing readmissions
Nodexus, a cancer screening/liquid biopsy company.
Nodexus is commercializing a versatile system, consisting of a hardware platform (tablet-sized) and disposable cartridges, that was developed at Princeton University and the University of California, Berkeley. The technology offers unprecedented sensitivity at a fraction of the cost, and it is leveraging our unique advantages for cancer screening.
Unlike existing technologies for CTC detection, Nodexus' platform enables the collection and characterization of many different types of viable CTCs that can ultimately allow a doctor to identify the right regimen for each patient, monitor therapy resistance, and perform early detection of disease. Its liquid biopsy provides an avenue for new therapies and drug discovery while reducing costs/labor time and increasing patient outcomes/peace-of-mind. A unique benefit offered by our system is its ease of use; it is a one-step fully automated process that can be operated without the need for a trained technician.
Stroll Health, a company that assists doctors with making specialist referrals.
Stroll provides a tablet-based tool for physicians to share the cost and location of upcoming care options, enabling patients to discover in-network locations of which the doctor was unaware and utilize potentially better but certainly cheaper and more convenient options. Procedure cost and patient data come directly from the insurers’ negotiated rate and patient databases.
The projected out-of-pocket cost is based on the patient’s deductible status and displayed in real-time. The first release focuses on six radiology diagnostics: MRI, CT, X-ray, PET, ultrasound, and mammogram scans, but will expand to Rx and other treatments. The app will also receive prior authorization numbers automatically and send orders electronically.
Cloudwear, a security solution to prevent unauthorized access to health care data and online cloud accounts
Cloudwear leverages and integrates capabilities found on most smart phones—including GPS location detection, fingerprint sensors, and image sensors—along with real-time wireless network information to add new anti-fraud security protection to any cloud account. Cloudwear provides online account protection that is stronger than two-factor authentication.
Here is what the winner of Vator Splash Health will receive:
A video of their presentation a bottle of Bread and Butter wine; a $24k annual subscription to Rackspace services; and a Shine from Misfit Wearables.
The overall winner receives a two-hour consultation with KPMG; free bookkeeping services courtesy Scrubbed; two-man months of one IOS's developer's time (equivalent to $10k); AND one-hour sit-down meetings withCanvas Venture Fund, Bessemer Venture Partners, Felicis Ventures,InterWest, Lux Capital, Maveron, Norwest Venture Partners, ONSET Ventures, Box, Prolog Ventures, and Obvious Ventures plus a Vator backpack and t-shirt!
We are stoked to have Rackspace be our preferred provider for our startup finalists.
Support VatorNews by Donating
Read more from our "The Future of Healthcare" series
Investments into precision medicine companies is rising, but how much has it helped?Read more...
Simcox will be a part of Vator's Healthcare in Politics salon on October 7Read more...
Related Companies, Investors, and Entrepreneurs
Joined Vator on
Stroll Health helps health providers effectively manage patients and deliver better value care. By personalizing each patient journey and offering seamless access to care choices that are convenient, covered, and affordable, Stroll drives higher patient retention, lowers operating costs, and delivers a vastly improved patient experience. At the 2016 Health 2.0, we were named the most fundable enterprise health startup of the year. We're raising a seed to accelerate provider system growth.
Joined Vator on
Privail is developing point-of-care (POC) diagnostics for the early detection of infectious diseases, with an initial focus on HIV. Unlike current POC diagnostic methods, which focus on the detection of antibodies or nucleic acids, Privail's proprietary technology directly detects the virus itself and is available in a simple, low-cost and portable device. By getting tested immediately, patients can receive earlier and more effective treatment, and ultimately reduce the spread of disease.
There is a lack of early HIV identification and treatment. Today, over 54% of the 35 million HIV+ population are unaware of their disease status until symptoms appear, and as a result, are 11 times more likely to die within their first year of infection. This unawareness also increases the risk of spreading HIV. Current diagnostics, which rely on the detection of antibodies or nucleic acids, present barriers to early testing because of their high costs and long window periods. Additionally, in regions such as Africa and India, where more than 80% of the HIV population resides, social stigma associated with getting tested creates an additional barrier.
Privail is developing simple, low-cost, and portable POC diagnostics for the detection and monitoring of infectious and inflammatory diseases. Our device will lie at the intersection between a pregnancy test and diabetes test, where all that is required is a small amount of blood from a finger prick, and within minutes, a patient will obtain easy-to-read results in the form of a color output (red or blue) or a digital output (“+” or “-“). Similarly, we will also be providing a laboratory test for hospital/clinical use, where a small patient blood sample can be mixed with Privail’s testing solution, and within minutes, results can be read with standard laboratory equipment. Furthermore, Privail’s proprietary technology is a platform that can be easily adapted for the early detection of a spectrum of diseases. Hence, there is huge future potential to impact the lives of those at risk for common diseases as well as upcoming threats.
By providing affordable tests that can be conducted in the privacy of one's home, we set the stage for enhanced health outcomes on a global level. The earlier a disease is detected, the better patients can enhance health outcomes and avoid disease transmission.
Joined Vator on
Nodexus is commercializing a versatile system, consisting of a hardware platform (tablet-sized) and disposable cartridges, that was developed at Princeton University and the University of California, Berkeley. The technology offers unprecedented sensitivity at a fraction of the cost, and we are leveraging our unique advantages for cancer screening.
Studies have shown that circulating tumor cells (CTCs) shed from a patient’s primary tumor and enter the bloodstream, leading to the formation of secondary tumors elsewhere in the body. The presence of CTCs is linked to metastases, decreased survival rates, and therapy inefficacy; therefore, CTCs can serve as an early warning system for the spread of cancer.
The Nodexus Solution
We believe that the future of metastatic cancer screening, treatment, and monitoring will be through a “liquid biopsy”. Unlike existing technologies for CTC detection, our platform enables the collection and characterization of many different types of viable CTCs that can ultimately allow a doctor to identify the right regimen for each patient, monitor therapy resistance, and perform early detection of disease. Our liquid biopsy provides an avenue for new therapies and drug discovery while reducing costs/labor time and increasing patient outcomes/peace-of-mind. A unique benefit offered by our system is its ease of use; it is a one-step fully automated process that can be operated without the need for a trained technician.
Karthik Balakrishnan, PhD – Chief Executive Officer, (Ph.D. in Mechanical Engineering, UC Berkeley, B.S. Mechanical Engineering, Caltech; M.S. Mechanical Engineering, UC Berkeley), Full-Time – Karthik has extensive experience with the Nodexus platform, as a co-inventor of the core technology. He provides insight into the manufacturing and development that are necessary to commercialize the platform. Karthik’s vision is to apply device design and engineering to solve medical problems and to develop commercial solutions to improve patient outcomes.
Anand Kesavaraju – Chief Strategy Officer, (Innovation Fellow, Northwestern University INVO; B.S. Bioengineering, UC Berkeley; M.S. Biomedical Engineering, Northwestern University), Full-Time – Anand has done extensive research in Biological Engineering and Global Health, has professional experience in the biomedical device industry, and has entrepreneurship expertise through the NUvention Medical Innovation Program and as an Innovation Fellow at INVO. Anand’s background lies in the translation of biomedical devices from ideation to the market.
Vincent Tuminelli – Chief Product Officer, (Business development in Biotechnology; A.B. Biology, Princeton University), Full-Time – Vincent has spent years in the biotech industry. He has extensive research, development, and industry experience in the biotechnology sector (Genentech, Plexxikon), including leading budget and contract negotiations. Vincent brings expertise working with contract research organizations and pharmaceutical companies that will prove valuable as Nodexus grows.
Furthermore, Nodexus’ key personnel are joined by a strong team of Advisors and Scientific Advisors that will be assisting with development and commercialization.
Frequently Asked Q&A
Please see Document entitled Nodexus - Due Diligence Q&A in Private folder
Joined Vator on
Luminate Health provides labs and healthcare providers with a first-of-its-kind, digital platform for their patients to access and understand their lab results. The company is a SaaS provider, and is partnering with commercial, specialty, and hospital labs across the US. Luminate Health is also helping these labs satisfy a major new federal rule from HHS, which now requires all US labs - commercial, specialty, and hospital - to provide patients with direct access to their lab results.
Luminate Health now counts a number of top-150 US labs among its customers, and continues to see a very positive response to its product from both patients and physicians.
Luminate Health is focused on leading the shift toward patient-centric healthcare by engaging patients to actively manage their own health, and leveraging the growing volume of available health data to improve patient care and outcomes.
The company is venture-backed, and includes KEC Ventures and several prominent healthcare-focsed angels as investors.
Joined Vator on
Core Mobile is enhancing digital health by harnessing the power of mobile, real time data, AI and machine learning to increase access to care and improve patient outcomes.
Core Mobile products and solutions are HIPAA and FISMA certified by US Federal Government as shown at,
Core Mobile has won multi-year multi-million dollar contracts from Veterans Affairs Medical Centers.
Core Mobile solutions are sold by DELL Technologies worldwide including Europe and Middle-East.
Core Mobile offers guaranteed Return on Investment between 300% and 600% with multiple metrics of measurement as listed below.
Improve Efficiency & Access to Care
‐Reduce cancellations / delays / no-shows 5% to 40%
‐Increase patient throughput 5% to 20%
‐Increase block usage time up to 95%
Increased Virtual Visits
Improve Patient & Staff Satisfaction
Improve Patient Outcomes
‐Reduction in readmissions 5% to 20%
Improve ICU Nurse-Patient Ratio 1:2 to 1:5 to targeted goal of 1:30
Core Mobile became cash flow positive in 2019.
Core Mobile raising capital to scale the business to address $150M opportunity at VA, $100M opportunity at DHA, and overall $950M opportunity worldwide in the next 3 years.